Pediatrics

Myopia-control spectacle lenses reduce short-term progression in children by about 50%, though efficacy and long-term durability vary.

NEI-funded US trial compares HALT MAX lenses, 0.05% atropine, and combination therapy to slow childhood myopia and axial elongation.

As of July 13, 2026, a meeting date has not been set.

Screen time's derailing of the circadian rhythm could contribute to behavioral difficulties in pediatric patients.

Choosing the right patients for soft lenses, orthokeratology, and spectacle lenses has long-lasting effects on the vision health of those with myopia.

The free web-based tool guides eye care providers through evidence-based amblyopia diagnosis and treatment without requiring pediatric subspecialty training.

Researchers analyzed data from 13 randomized controlled trials involving children and adolescents with myopia.

For Erin Tomiyama, OD, PhD, FAAO, managing myopia in pediatric patients involves decisions that extend well beyond updating a glasses prescription.

Maria Liu, OD, PhD, MPH, MBA, FAAO, is taking the recent decision as an opportunity to reassess the role atropine plays in myopia control.

This study sheds light on use of the 0.05% atropine, which has been reported to be effective against myopia progression in some but not all studies.

For Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, low-atropine options are a must for eye care providers in the treatment of myopia.

Michael Raizman, MD, and colleagues evaluated the efficacy and safety of epithelium-on oxygen-enriched corneal CXL in a sub-group analysis of 30 eyes of 22 pediatric patients aged 13 to 17 years.

The study was carried out between July 8 and August 1, 2024, and included 127 eyes from 68 children aged 8–14 years.

Dye, OD, details exciting new trials for amblyopia that are in the works at NYU Langone Eye Center.

Today’s tools let clinicians fine-tune fits with accuracy, while solving old challenges and unlocking complex optical corrections.

The trial met its primary efficacy and key secondary end points.

One in 3 children worldwide has myopia, and the prevalence is rising so steadily that if it continues as predicted, there will be more than 740 million pediatric cases by 2050.

Boston event will shed light on cerebral/cortical visual impairment (CVI), a leading cause of pediatric blindness

Ocular salvage and preservation of vision are essentially dependent on early diagnosis, and several studies have been conducted to identify the factors leading to delayed diagnosis at presentation.

Santen introduces low-dose atropine in Germany, marking a significant advancement in myopia management for children amid a global epidemic.

New research reveals collagen mimetic peptides may effectively restore ocular tissue stiffness, offering hope for myopia and other eye diseases.

A recent study reveals that ADHD in schoolchildren correlates with lower myopia prevalence and shorter eye length, suggesting intriguing links between vision and attention disorders.

The primary study outcomes were the cumulative incidence rate of myopia, with myopia defined as an SER −0.50 diopter (D) or less and the percentage of participants who had a fast myopic shift that was defined as a spherical equivalent myopic shift of 0.50 D or greater over the course of 1 year.

A study reveals that secondhand smoke significantly increases the risk of myopia in Chinese children, highlighting the need for smoke-free environments.